To include your compound in the COVID-19 Resource Center, submit it here.

iPharma gets rights to Boehringer's FAK inhibitor

Boehringer Ingelheim GmbH (Ingelheim, Germany) granted iPharma Ltd. exclusive, worldwide rights to develop

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE